Pressure-Adjusted Heart Rate by Echocardiography and Mortality in the Cardiac Intensive Care Unit Authors: Kirsten M. Lipps, Ashley M. Darlington, Garima Dahiya, Dustin B. Hillerson, David D. Berg, Bradley W. Ternus, Courtney E. Bennett, Jacob C. Jentzer Published: 2026 ABSTRACT BackgroundPressure-adjusted heart rate (HR) (PAHR) provides an integrated assessment of hemodynamic decompensation in critical illness.ObjectivesWe aimed to evaluate the association of noninvasively obtained PAHR and mortality in cardiac intensive care unit (CICU) patients.MethodsThis was a retrospective cohort of patients with a transthoracic echocardiogram (TTE) within 24 hours of admission to an academic CICU (2007-2018). HR, right atrial pressure (RAP), and mean arterial pressure (MAP) obtained from the TTE were used to calculate PAHR as RAP · HR/MAP (in beats/min). The primary outcome was in-hospital mortality and secondary outcome was one-year mortality.ResultsAmong 5,411 patients (median 70.1 years, 38.6% female, 92.4% White), higher PAHR was associated with greater acute illness severity, comorbidities, and critical care therapy utilization. The median PAHR was higher among patients who died while hospitalized (14.3 beats/min vs 6.8 BPM; P < 0.001). Echocardiographic measurements of biventricular function, filling pressures, and cardiac output were worse among those with higher PAHR. In-hospital mortality (adjusted OR: 1.03; 95% CI: 1.01 to 1.05; P = 0.001) and one-year (adjusted HR: 1.03; 95% CI: 1.02-1.04; P < 0.001) mortality increased with each 1 BPM higher PAHR. PAHR had moderate discrimination for in-hospital mortality (C-statistic 0.75).ConclusionsPAHR is a readily determinable composite measure of cardiovascular status that enhances clinical risk stratification of critically ill patients, performing better than MAP, HR, and Modified Shock Index. Among CICU patients, higher PAHR by TTE was associated with greater mortality. The contemporary cardiac intensive care unit (CICU) admits an increasingly complex and heterogeneous patient population with acute and chronic heart disease, circulatory failure, and multiorgan dysfunction.1,2 This results in a wide spectrum of patient acuity, severity of illness, and mortality risk. Separating high-risk and low-risk individuals early during the course of CICU admission can improve patient triage and resource allocation, making risk stratification in CICU populations an important priority. Several existing and novel multicomponent risk scores can be used for this purpose, but simpler methods that can be applied at the bedside are lacking. Easy-to-calculate indices such as the Shock Index and Modified Shock Index, which incorporate heart rate (HR) and systemic blood pressure, can indicate which individuals are at elevated risk of adverse outcomes. However, these have only modest performance in the CICU.3,4 Almost 30 years ago, the concept of pressure-adjusted HR (PAHR) was introduced as a component of the Multiple Organ Dysfunction Score. PAHR incorporates right atrial pressure (RAP) into the Modified Shock Index to provide a more integrated measure of cardiovascular status.5 Although initially validated for the surgical intensive care unit, PAHR has also shown value in patients with septic shock and those with cardiogenic shock.5, 6, 7, 8, 9, 10 A key limitation of PAHR as used in the Multiple Organ Dysfunction Score is the need for an invasive RAP measurement via central venous catheterization. Echocardiography is an accurate, reliable, and noninvasive method to obtain hemodynamic data at the point-of-care (eg, point-of-care cardiac ultrasound).11,12 Although numerous advanced hemodynamic parameters that have prognostic value among CICU patients can be obtained via transthoracic echocardiogram (TTE),13 a key advantage is the ability to quickly estimate RAP and thus PAHR.14,15 However, no prior studies have either evaluated PAHR in a diverse CICU patient population or used TTE to calculate PAHR for prognostic purposes. Accordingly, the objective of this study was to evaluate the association between PAHR and mortality among a large, diverse CICU population, using noninvasively derived RAP. Methods Study population This retrospective cohort study was approved by the Mayo Clinic Institutional Review Board as minimal risk for patients who had previously consented to have their medical records included in observational research. We extracted patients from a previously constructed database of consecutive, unique adults (≥18 years-old) admitted to the CICU at Mayo Clinic (Rochester, Minnesota) between January 2007 and April 2018. We did not include admissions after April 2018 given this was a historical database. Only patients who had a TTE completed within 24 hours of CICU admission, with available data to calculate PAHR at the time of TTE, were eligible for study inclusion. Data sources Demographic, clinical, laboratory, and outcome data were extracted from the electronic medical record as previously described.2 Admission diagnoses were defined as all International Classification of Disease 9/10 diagnosis codes recorded within 24 hours of CICU admission.16 Previously validated algorithms were used to determine the Charlson Comorbidity Index and component comorbidities as well as acute illness severity scores, including Acute Physiology and Chronic Health Evaluation III, Sequential Organ Failure Assessment, and Mayo Clinic CICU Admission Risk Score.2,17, 18, 19 TTE data were extracted from the electronic medical record, as previously described (Supplemental Tables 1 and 2)13,20, 21, 22, 23, 24 RAP was directly measured if an invasive value was available; otherwise, it was estimated from inferior vena cava size and collapsibility by TTE according to contemporary guidelines (Appendix);25,26 we did not have data regarding which method of RAP measurement was used. PAHR was calculated using this RAP value and the recorded HR and mean arterial pressure (MAP), as documented on the TTE report, at the time of TTE as follows: PAHR = RAP · HR/MAP (in beats/min).5 In addition, the Modified Shock Index (HR/MAP), mean perfusion pressure (MAP − RAP), and MAP/RAP ratio were calculated. PAHR was categorized first using quartiles and then using simplified cutoffs of <10 BPM, 10 to 20 BPM, and >20 BPM. Numerous Doppler-based hemodynamic measurements and derived parameters were also calculated from the TTE, as previously reported (Supplemental Table 2).13,20, 21, 22, 23, 24 The severity of left ventricular systolic dysfunction was determined based on left ventricular ejection fraction using American Society of Echocardiography criteria.27 The severity of right ventricular systolic dysfunction was determined by the interpreting cardiologist based on all available data TTE.25 Biventricular dysfunction was defined by the presence of moderate or greater left ventricular systolic dysfunction and moderate or greater right ventricular systolic dysfunction. Outcomes The primary outcome of interest was all-cause in-hospital mortality (including CICU deaths), and the secondary outcome was all-cause one-year mortality. Mortality data were extracted from the electronic health record and state/local databases. Statistical analysis Continuous variables were summarized as median (interquartile range, 25th percentile-75th percentile), and groups were compared using the Kruskal-Wallis rank-sum test. Categorical variables were summarized as number (percent), and groups were compared using chi-square tests. For the primary outcome, locally estimated scatterplot smoother curves were used to examine the association between PAHR and in-hospital mortality. Unadjusted and multivariable adjusted logistic regression models were used to evaluate potential predictors of in-hospital mortality, with odds ratios (ORs) and 95% Confidence Intervals (CIs) reported. Receiver operating curve analysis was performed to calculate the area under the receiver operating curve (AUC) (C-statistic) for each potential predictor of in-hospital mortality, with models compared using De Long test. For the secondary outcome, Kaplan-Meier curves were used to evaluate 1-year mortality, and groups were compared using the log-rank test. Unadjusted and multivariable adjusted Cox-proportional hazard regression models were used to evaluate potential predictors of one-year mortality, with hazard ratios (HRs) and 95% CIs reported. Multivariable models were adjusted for the following known confounders a priori: age, sex, race, Charlson Comorbidity Index, Mayo Clinic CICU Admission Risk Score, rhythm at TTE (sinus or atrial fibrillation), acute coronary syndrome, heart failure, number of vasoactive drugs, mechanical ventilation, dialysis, and coronary catheterization/percutaneous coronary intervention. All P values are 2-tailed, and a P value <0.05 was considered statistically significant. Analyses were performed using BlueSky (10.3.1 Pro; BlueSky LLC). Results Study population Of the 12,428 unique CICU patients, 7,444 had a TTE within 1 day of CICU admission, and the rest were excluded. Of the potentially eligible patients, 5,441 had available data to calculate PAHR, and the remaining patients were excluded due to lack of RAP in 1,694, HR in 631, and MAP in 449 (total N = 2,003 with missing PAHR). This final study population had a median age of 70.1 (59.4, 79.8) years and included 2,101 (38.6%) females and 5,029 (92.4%) White patients (Table 1). Admission diagnoses included acute coronary syndrome in 2,957 (54.9%), ST-segment elevation myocardial infarction in 1,775 (32.6%), heart failure in 2,755 (51.1%), shock in 882 (16.4%), and cardiac arrest in 682 (12.7%). Cardiogenic shock was present in 734 patients (13.5%). Critical care therapies were used in 3,088 patients (56.8%), including positive pressure ventilation in 1,534 (28.2%) and vasoactive drugs in 1,209 (22.2%).Table 1Patient Characteristics, Illness Severity Scores, and Critical Care Therapy Utilization, by PAHR QuartilePAHR Quartile1 (n = 1,361)2 (n = 1,360)3 (n = 1,361)4 (n = 1,359)PAHR, BPM, median (IQR)3.6 (3.2, 4.0)5.3 (4.8, 6.2)9.9 (8.5, 11.3)18.1 (15.4, 22.3)Age, years, median (IQR)67.7 (57.4, 78.6)69.7 (58.6, 79.0)71.3 (61.3, 81.5)71.5 (60.8, 80.6)Chronic HF, n (%)103 (7.6)171 (12.6)254 (18.7)401 (29.6)Previous ACS, n (%)227 (16.7)258 (19.0)268 (19.7)229 (16.9)CCI, median (IQR)1.0 (0.0, 3.0)1.0 (0.0, 3.0)2.0 (0.0, 4.0)2.0 (1.0, 4.0)APACHE III, median (IQR)48.0 (36.0, 60.0)54.0 (42.0, 68.0)62.0 (49.0, 75.0)71.0 (57.0, 89.0)SOFA, median (IQR)1.0 (1.0, 2.0)2.0 (1.0, 4.0)3.0 (1.0, 5.0)5.0 (3.0, 8.0)ACS, n (%)855 (63.8)837 (62.0)710 (52.7)555 (41.1)Decompensated HF, n (%)341 (25.4)564 (41.8)792 (58.8)1,058 (78.3)Shock, n (%)57 (4.3)135 (10.0)224 (16.6)466 (34.5)Cardiogenic shock, n (%)46 (3.4)102 (7.6)189 (14.0)397 (29.4)Cardiac arrest, n (%)102 (7.6)137 (10.2)190 (14.1)253 (18.7)In-hospital cardiac arrest, n (%)20 (1.5)19 (1.4)27 (2.0)57 (4.2)Respiratory failure, n (%)91 (6.8)266 (19.7)421 (31.2)637 (47.2)Sepsis, n (%)15 (1.1)64 (4.7)87 (6.5)194 (14.4)Vasoactives, n (%)90 (6.6)187 (13.8)302 (22.2)630 (46.4)Inotropes, n (%)12 (0.9)43 (3.2)92 (6.8)246 (18.1)Ventilator, n (%)123 (9.0)279 (20.5)441 (32.4)691 (50.8)Dialysis, n (%)14 (1.0)28 (2.1)51 (3.7)126 (9.3)IABP, n (%)74 (5.4)111 (8.2)112 (8.2)209 (15.4)Transfusion, n (%)54 (4.0)128 (9.4)172 (12.6)251 (18.5)Coronary angiogram, n (%)965 (70.9)904 (66.5)826 (60.7)703 (51.7)PCI, n (%)718 (52.8)639 (47.0)494 (36.3)323 (23.8)ACS = acute coronary syndrome; APACHE = Acute Physiology and Chronic Health Evaluation; CCI = Charlson Comorbidity Index; HF = heart failure; IABP = intra-aortic balloon pump; PAHR = pressure-adjusted heart rate; PCI = percutaneous coronary intervention; SOFA = Sequential Organ Failure Assessment. Table 1Patient Characteristics, Illness Severity Scores, and Critical Care Therapy Utilization, by PAHR QuartilePAHR Quartile1 (n = 1,361)2 (n = 1,360)3 (n = 1,361)4 (n = 1,359)PAHR, BPM, median (IQR)3.6 (3.2, 4.0)5.3 (4.8, 6.2)9.9 (8.5, 11.3)18.1 (15.4, 22.3)Age, years, median (IQR)67.7 (57.4, 78.6)69.7 (58.6, 79.0)71.3 (61.3, 81.5)71.5 (60.8, 80.6)Chronic HF, n (%)103 (7.6)171 (12.6)254 (18.7)401 (29.6)Previous ACS, n (%)227 (16.7)258 (19.0)268 (19.7)229 (16.9)CCI, median (IQR)1.0 (0.0, 3.0)1.0 (0.0, 3.0)2.0 (0.0, 4.0)2.0 (1.0, 4.0)APACHE III, median (IQR)48.0 (36.0, 60.0)54.0 (42.0, 68.0)62.0 (49.0, 75.0)71.0 (57.0, 89.0)SOFA, median (IQR)1.0 (1.0, 2.0)2.0 (1.0, 4.0)3.0 (1.0, 5.0)5.0 (3.0, 8.0)ACS, n (%)855 (63.8)837 (62.0)710 (52.7)555 (41.1)Decompensated HF, n (%)341 (25.4)564 (41.8)792 (58.8)1,058 (78.3)Shock, n (%)57 (4.3)135 (10.0)224 (16.6)466 (34.5)Cardiogenic shock, n (%)46 (3.4)102 (7.6)189 (14.0)397 (29.4)Cardiac arrest, n (%)102 (7.6)137 (10.2)190 (14.1)253 (18.7)In-hospital cardiac arrest, n (%)20 (1.5)19 (1.4)27 (2.0)57 (4.2)Respiratory failure, n (%)91 (6.8)266 (19.7)421 (31.2)637 (47.2)Sepsis, n (%)15 (1.1)64 (4.7)87 (6.5)194 (14.4)Vasoactives, n (%)90 (6.6)187 (13.8)302 (22.2)630 (46.4)Inotropes, n (%)12 (0.9)43 (3.2)92 (6.8)246 (18.1)Ventilator, n (%)123 (9.0)279 (20.5)441 (32.4)691 (50.8)Dialysis, n (%)14 (1.0)28 (2.1)51 (3.7)126 (9.3)IABP, n (%)74 (5.4)111 (8.2)112 (8.2)209 (15.4)Transfusion, n (%)54 (4.0)128 (9.4)172 (12.6)251 (18.5)Coronary angiogram, n (%)965 (70.9)904 (66.5)826 (60.7)703 (51.7)PCI, n (%)718 (52.8)639 (47.0)494 (36.3)323 (23.8)ACS = acute coronary syndrome; APACHE = Acute Physiology and Chronic Health Evaluation; CCI = Charlson Comorbidity Index; HF = heart failure; IABP = intra-aortic balloon pump; PAHR = pressure-adjusted heart rate; PCI = percutaneous coronary intervention; SOFA = Sequential Organ Failure Assessment. Patient Characteristics, Illness Severity Scores, and Critical Care Therapy Utilization, by PAHR Quartile ACS = acute coronary syndrome; APACHE = Acute Physiology and Chronic Health Evaluation; CCI = Charlson Comorbidity Index; HF = heart failure; IABP = intra-aortic balloon pump; PAHR = pressure-adjusted heart rate; PCI = percutaneous coronary intervention; SOFA = Sequential Organ Failure Assessment. PAHR groups The median PAHR was 7.3 (4.3, 13.1) BPM, reflecting RAP 10.0 (5.0, 14.0) mm Hg, HR 73.0 (63.0, 87.0) BPM, MAP 81.3 (72.3, 91.7) mm Hg, and Modified Shock Index 0.9 (0.7, 1.1) BPM/mm Hg. When patients were separated according to PAHR quartiles, patients with higher PAHR values were sicker with higher illness severity scores, more comorbidities, and greater use of critical care therapies (Table 1). TTE findings differed across PAHR groups, and patients with higher PAHR had worse measures for most TTE measurements including biventricular function, filling pressures, and systemic forward flow (Table 2).Table 2Echocardiographic Parameters by PAHR QuartileaPAHR Quartile1 (n = 1,361)2 (n = 1,360)3 (n = 1,361)4 (n = 1,359)PAHR, BPM, median (IQR)3.6 (3.2, 4.0)5.3 (4.8, 6.2)9.9 (8.5, 11.3)18.1 (15.4, 22.3)LVEDD, mm, median (IQR)50.0 (47.0, 54.0)50.0 (46.0, 55.0)51.0 (46.0, 56.0)52.0 (46.0, 59.5)LVEF, %, median (IQR)56.0 (46.0, 63.0)52.0 (40.0, 61.0)48.0 (34.0, 60.0)38.0 (25.0, 57.0)SV, ml, median (IQR)87.0 (75.0, 102.0)79.0 (65.0, 93.0)75.0 (61.0, 88.0)59.5 (46.0, 75.0)CO, L/min median (IQR)5.5 (4.7, 6.3)5.7 (4.7, 6.8)5.4 (4.4, 6.5)5.1 (4.0, 6.5)CI, L/min/m2, median (IQR)2.7 (2.5, 3.1)2.9 (2.5, 3.5)2.8 (2.4, 3.3)2.6 (2.1, 3.3)Mitral annulus E/e', medial, median (IQR)11.4 (8.8, 15.0)12.9 (10.0, 17.5)16.0 (11.1, 23.3)16.7 (11.7, 25.0)RAP, mm Hg, median (IQR)5.0 (5.0, 5.0)5.0 (5.0, 5.0)10.0 (10.0, 14.0)15.0 (14.0, 20.0)TASV, cm/s, median (IQR)12.0 (11.0, 14.0)12.0 (10.0, 14.0)11.0 (9.0, 13.0)10.0 (7.0, 12.0)TAPSE, cm, median (IQR)0.7 (0.5, 0.8)0.5 (0.4, 0.7)0.4 (0.3, 0.5)0.3 (0.2, 0.4)RVSP, mm Hg, median (IQR)30.0 (26.0, 36.0)34.0 (28.0, 41.0)45.0 (37.0, 54.0)49.0 (41.0, 59.0)TAPSE/RVSP, cm/s · mm Hg-1, median (IQR)0.7 (0.5, 0.8)0.5 (0.4, 0.7)0.4 (0.3, 0.5)0.3 (0.2, 0.4)PA elastance, mm Hg/ml, median (IQR)0.3 (0.3, 0.4)0.4 (0.3, 0.6)0.6 (0.5, 0.8)0.8 (0.6, 1.1)CPO, mm Hg · L/min, median (IQR)1.1 (0.9, 1.3)1.0 (0.8, 1.3)1.0 (0.8, 1.2)0.8 (0.7, 1.1)CPI, mm Hg · L/min/m2, median (IQR)0.5 (0.5, 0.6)0.5 (0.4, 0.6)0.5 (0.4, 0.6)0.4 (0.3, 0.6)LVSWI, J/m2, median (IQR)45.6 (38.6, 54.2)36.1 (29.3, 44.2)34.2 (27.8, 42.7)24.4 (18.4, 30.7)RVSWI, J/m2, median (IQR)15.4 (12.1, 19.7)15.0 (11.4, 20.2)17.0 (12.3, 23.3)13.4 (9.2, 19.9)Biventricular function Normal RV/LV function, n (%)1,138 (84.0)958 (71.4)750 (55.9)430 (32.2) LV dysfunction, n (%)167 (12.3)290 (21.6)340 (25.4)326 (24.4) RV dysfunction, n (%)30 (2.2)51 (3.8)125 (9.3)217 (16.3) Biventricular dysfunction, n (%)19 (1.4)43 (3.2)126 (9.4)361 (27.1)CI = cardiac index; CO = cardiac output; CPI = cardiac power index; CPO = cardiac power output; E/e = ratio of early diastolic velocity to early diastolic tissue Doppler velocity; LV = left ventricular; LVEDD = left ventricular end-diastolic dimension; LVEF = left ventricular ejection fraction; LVSWI = left ventricular stroke work index; PA = pulmonary artery; RAP = right atrial pressure; RV = right ventricular; RVSP = right ventricular systolic pressure; RVSWI = right ventricular stroke work index; SV = stroke volume; TAPSE = tricuspid annulus plane systolic excursion; TASV = peak tricuspid annulus systolic velocity; other abbreviations as in Table 1.aHemodynamic variables are further defined in Supplemental Tables 1 and 2. Table 2Echocardiographic Parameters by PAHR QuartileaPAHR Quartile1 (n = 1,361)2 (n = 1,360)3 (n = 1,361)4 (n = 1,359)PAHR, BPM, median (IQR)3.6 (3.2, 4.0)5.3 (4.8, 6.2)9.9 (8.5, 11.3)18.1 (15.4, 22.3)LVEDD, mm, median (IQR)50.0 (47.0, 54.0)50.0 (46.0, 55.0)51.0 (46.0, 56.0)52.0 (46.0, 59.5)LVEF, %, median (IQR)56.0 (46.0, 63.0)52.0 (40.0, 61.0)48.0 (34.0, 60.0)38.0 (25.0, 57.0)SV, ml, median (IQR)87.0 (75.0, 102.0)79.0 (65.0, 93.0)75.0 (61.0, 88.0)59.5 (46.0, 75.0)CO, L/min median (IQR)5.5 (4.7, 6.3)5.7 (4.7, 6.8)5.4 (4.4, 6.5)5.1 (4.0, 6.5)CI, L/min/m2, median (IQR)2.7 (2.5, 3.1)2.9 (2.5, 3.5)2.8 (2.4, 3.3)2.6 (2.1, 3.3)Mitral annulus E/e', medial, median (IQR)11.4 (8.8, 15.0)12.9 (10.0, 17.5)16.0 (11.1, 23.3)16.7 (11.7, 25.0)RAP, mm Hg, median (IQR)5.0 (5.0, 5.0)5.0 (5.0, 5.0)10.0 (10.0, 14.0)15.0 (14.0, 20.0)TASV, cm/s, median (IQR)12.0 (11.0, 14.0)12.0 (10.0, 14.0)11.0 (9.0, 13.0)10.0 (7.0, 12.0)TAPSE, cm, median (IQR)0.7 (0.5, 0.8)0.5 (0.4, 0.7)0.4 (0.3, 0.5)0.3 (0.2, 0.4)RVSP, mm Hg, median (IQR)30.0 (26.0, 36.0)34.0 (28.0, 41.0)45.0 (37.0, 54.0)49.0 (41.0, 59.0)TAPSE/RVSP, cm/s · mm Hg-1, median (IQR)0.7 (0.5, 0.8)0.5 (0.4, 0.7)0.4 (0.3, 0.5)0.3 (0.2, 0.4)PA elastance, mm Hg/ml, median (IQR)0.3 (0.3, 0.4)0.4 (0.3, 0.6)0.6 (0.5, 0.8)0.8 (0.6, 1.1)CPO, mm Hg · L/min, median (IQR)1.1 (0.9, 1.3)1.0 (0.8, 1.3)1.0 (0.8, 1.2)0.8 (0.7, 1.1)CPI, mm Hg · L/min/m2, median (IQR)0.5 (0.5, 0.6)0.5 (0.4, 0.6)0.5 (0.4, 0.6)0.4 (0.3, 0.6)LVSWI, J/m2, median (IQR)45.6 (38.6, 54.2)36.1 (29.3, 44.2)34.2 (27.8, 42.7)24.4 (18.4, 30.7)RVSWI, J/m2, median (IQR)15.4 (12.1, 19.7)15.0 (11.4, 20.2)17.0 (12.3, 23.3)13.4 (9.2, 19.9)Biventricular function Normal RV/LV function, n (%)1,138 (84.0)958 (71.4)750 (55.9)430 (32.2) LV dysfunction, n (%)167 (12.3)290 (21.6)340 (25.4)326 (24.4) RV dysfunction, n (%)30 (2.2)51 (3.8)125 (9.3)217 (16.3) Biventricular dysfunction, n (%)19 (1.4)43 (3.2)126 (9.4)361 (27.1)CI = cardiac index; CO = cardiac output; CPI = cardiac power index; CPO = cardiac power output; E/e = ratio of early diastolic velocity to early diastolic tissue Doppler velocity; LV = left ventricular; LVEDD = left ventricular end-diastolic dimension; LVEF = left ventricular ejection fraction; LVSWI = left ventricular stroke work index; PA = pulmonary artery; RAP = right atrial pressure; RV = right ventricular; RVSP = right ventricular systolic pressure; RVSWI = right ventricular stroke work index; SV = stroke volume; TAPSE = tricuspid annulus plane systolic excursion; TASV = peak tricuspid annulus systolic velocity; other abbreviations as in Table 1.aHemodynamic variables are further defined in Supplemental Tables 1 and 2. Echocardiographic Parameters by PAHR Quartilea CI = cardiac index; CO = cardiac output; CPI = cardiac power index; CPO = cardiac power output; E/e = ratio of early diastolic velocity to early diastolic tissue Doppler velocity; LV = left ventricular; LVEDD = left ventricular end-diastolic dimension; LVEF = left ventricular ejection fraction; LVSWI = left ventricular stroke work index; PA = pulmonary artery; RAP = right atrial pressure; RV = right ventricular; RVSP = right ventricular systolic pressure; RVSWI = right ventricular stroke work index; SV = stroke volume; TAPSE = tricuspid annulus plane systolic excursion; TASV = peak tricuspid annulus systolic velocity; other abbreviations as in Table 1. Hemodynamic variables are further defined in Supplemental Tables 1 and 2. In-hospital mortality A total of 432 (7.9%) patients died during hospitalization, including 269 (4.9%) in the CICU. The median PAHR was significantly higher among in-hospital deaths (14.3 BPM vs 6.8 BPM, P < 0.001), reflecting higher values for RAP and HR with lower MAP. In-hospital mortality increased incrementally with higher PAHR (Figure 1); although review of the estimated scatterplot smoother curve did not show an obvious inflection point for the association between PAHR and in-hospital mortality, Classification and Regression Tree analysis identified PAHR cutoffs of 14 and 22 BPM. A stepwise increase in mortality was seen across PAHR groups overall and according to admission diagnoses (Central Illustration); similar patterns were seen for patients with and without atrial fibrillation, mechanical ventilation, or vasoactive drug therapy (Figure 2). Likewise, PAHR was associated with incrementally higher mortality when stratified by left ventricular and right ventricular systolic dysfunction (Figure 3).Figure 1Locally Estimated Scatterplot Smoother Curve Representing the Association Between PAHR and In-Hospital MortalityIn-hospital mortality increased incrementally with higher PAHR, although the LOESS curve does not show an obvious inflection point.Central IllustrationPressure-Adjusted Heart Rate in CICU PatientsAmong patients admitted to the CICU, PAHR is strongly associated with in-hospital mortality, regardless of admission diagnosis, performing better than component variables and the Modified Shock Index (HR/MAP) on receiver operating curve analysis. Admission PAHR is also strongly predictive of 1-year mortality among CICU patients. ACS = acute coronary syndrome; BPM = beats per minute; CA = cardiac arrest; CICU = cardiac intensive care unit; CS = cardiogenic shock; HF = heart failure; HR = heart rate; MAP = mean arterial pressure; MPP = mean perfusion pressure; mSI = Modified Shock Index; PAHR = pressure-adjusted heart rate; TTE = transthoracic echocardiogram; RAP = right atrial pressure.Figure 2In-Hospital Mortality Stratified by Pressure-Adjusted Heart Rate Subgroups of Rhythm and TherapiesA stepwise increase in in-hospital mortality was observed across PAHR groups according to rhythm (sinus rhythm or atrial fibrillation) at time of TTE (sinus rhythm or atrial fibrillation), use of invasive mechanical ventilation, and use of vasoactive medications. AF = atrial fibrillation; BPM = beats per minute; SR= sinus rhythm; vent = invasive mechanical ventilation.Figure 3In-Hospital Mortality Stratified by Pressure-Adjusted Heart Rate Subgroups of Cardiac FunctionPAHR was associated with incrementally higher mortality when stratified by (A) left ventricular systolic dysfunction and (B) right ventricular systolic dysfunction. ASE = American Society of Echocardiography; LVEF = left ventricular ejection fraction; LVSD = left ventricular systolic dysfunction; RV = right ventricular; RVSD = right ventricular systolic dysfunction; TTE = transthoracic echocardiogram; other abbreviations as in Figure 2. Locally Estimated Scatterplot Smoother Curve Representing the Association Between PAHR and In-Hospital Mortality In-hospital mortality increased incrementally with higher PAHR, although the LOESS curve does not show an obvious inflection point. Pressure-Adjusted Heart Rate in CICU Patients Among patients admitted to the CICU, PAHR is strongly associated with in-hospital mortality, regardless of admission diagnosis, performing better than component variables and the Modified Shock Index (HR/MAP) on receiver operating curve analysis. Admission PAHR is also strongly predictive of 1-year mortality among CICU patients. ACS = acute coronary syndrome; BPM = beats per minute; CA = cardiac arrest; CICU = cardiac intensive care unit; CS = cardiogenic shock; HF = heart failure; HR = heart rate; MAP = mean arterial pressure; MPP = mean perfusion pressure; mSI = Modified Shock Index; PAHR = pressure-adjusted heart rate; TTE = transthoracic echocardiogram; RAP = right atrial pressure. In-Hospital Mortality Stratified by Pressure-Adjusted Heart Rate Subgroups of Rhythm and Therapies A stepwise increase in in-hospital mortality was observed across PAHR groups according to rhythm (sinus rhythm or atrial fibrillation) at time of TTE (sinus rhythm or atrial fibrillation), use of invasive mechanical ventilation, and use of vasoactive medications. AF = atrial fibrillation; BPM = beats per minute; SR= sinus rhythm; vent = invasive mechanical ventilation. In-Hospital Mortality Stratified by Pressure-Adjusted Heart Rate Subgroups of Cardiac Function PAHR was associated with incrementally higher mortality when stratified by (A) left ventricular systolic dysfunction and (B) right ventricular systolic dysfunction. ASE = American Society of Echocardiography; LVEF = left ventricular ejection fraction; LVSD = left ventricular systolic dysfunction; RV = right ventricular; RVSD = right ventricular systolic dysfunction; TTE = transthoracic echocardiogram; other abbreviations as in Figure 2. Each 1 BPM higher PAHR was associated with higher risk of in-hospital mortality (unadjusted OR: 1.10; 95% CI: 1.09-1.12; P < 0.001). Each higher PAHR quartile conferred greater risk of death (unadjusted OR: 2.43 per each higher quartile; 95% CI: 2.18-2.73; P < 0.001), with a substantially higher risk in the highest quartile vs the lowest (unadjusted OR: 16.65; 95% CI: 10.56-28.02; P < 0.001). Patients with PAHR 10 to 20 BPM (unadjusted OR: 4.00; 95% CI: 3.17-5.07; P < 0.001) or >20 BPM (unadjusted OR: 7.50; 95% CI: 5.69-9.89; P < 0.001) were at higher risk of in-hospital mortality. By receiver operating curve analysis, PAHR had the highest AUC C-statistic (0.75) of its component values of HR, MAP, RAP, Modified Shock Index, and RAP/MAP ratio and when compared to mean perfusion pressure (all P < 0.001 by De Long test) (Central Illustration, Table 3). In addition, PAHR had superior discrimination to both left ventricular outflow tract velocity time integral (AUC: 0.71) and left ventricular stroke work index (AUC: 0.74), and this was statistically significant (both P < 0.001).Table 3Logistic Regression Models Showing Unit OR Values for Component Parts of PAHR as Predictors of In-Hospital MortalityUnadjusted OR (95% CI)P ValueAdjusted OR (95% CI)P ValueUnadjusted AUC (95% CI)ROCP Value vs PAHRHR1.026 (1.022-1.031)<0.0011.013 (1.006-1.019)<0.0010.6579 (0.6306-0.6851)<0.001MAP0.970 (0.963-0.977)<0.0010.996 (0.987-1.004)0.350.6186 (0.5900-0.6472)<0.001RAP1.136 (1.116-1.156)<0.0011.026 (1.001-1.052)0.0380.6952 (0.6707-0.7196)<0.001MPP0.959 (0.953-0.966)<0.0010.994 (0.985-1.002)0.120.6719 (0.6449-0.6989)<0.001RAP/MAP9,918.1 (3,098.1-31,994.9)<0.0016.193 (1.194-31.777)0.0290.7210 (0.6971-0.7450)<0.001mSI7.093 (5.352-0.413)<0.0012.101 (1.432-3.075)0.0010.6896 (0.6628-0.7164)<0.001PAHR1.102 (1.089-1.115)<0.0011.0289 (1.011-1.047)0.0120.7475 (0.7255-0.7696)NALogistic regression models showing unit OR values (per each 1-unit higher) for component parts of PAHR and PAHR (per 1 BPM higher) as predictors of in-hospital mortality. Models were adjusted for the following covariates: age, sex, race, Charlson Comorbidity Index, acute illness severity scores, rhythm (sinus rhythm vs atrial fibrillation) at transthoracic echocardiogram (sinus rhythm vs atrial fibrillation), acute coronary syndrome, heart failure, number of vasoactive drugs, invasive mechanical ventilation, dialysis, and coronary catheterization/percutaneous coronary intervention. P value for receiver operating curve comparison to PAHR represents De Long test.AUC = area under the receiver operating curve; HR = heart rate; MAP = mean arterial pressure; MPP = mean perfusion pressure; mSI = Modified Shock Index; NA = not applicable; ROC = receiver operating curve; other abbreviations as in Tables 1 and 2. Table 3Logistic Regression Models Showing Unit OR Values for Component Parts of PAHR as Predictors of In-Hospital MortalityUnadjusted OR (95% CI)P ValueAdjusted OR (95% CI)P ValueUnadjusted AUC (95% CI)ROCP Value vs PAHRHR1.026 (1.022-1.031)<0.0011.013 (1.006-1.019)<0.0010.6579 (0.6306-0.6851)<0.001MAP0.970 (0.963-0.977)<0.0010.996 (0.987-1.004)0.350.6186 (0.5900-0.6472)<0.001RAP1.136 (1.116-1.156)<0.0011.026 (1.001-1.052)0.0380.6952 (0.6707-0.7196)<0.001MPP0.959 (0.953-0.966)<0.0010.994 (0.985-1.002)0.120.6719 (0.6449-0.6989)<0.001RAP/MAP9,918.1 (3,098.1-31,994.9)<0.0016.193 (1.194-31.777)0.0290.7210 (0.6971-0.7450)<0.001mSI7.093 (5.352-0.413)<0.0012.101 (1.432-3.075)0.0010.6896 (0.6628-0.7164)<0.001PAHR1.102 (1.089-1.115)<0.0011.0289 (1.011-1.047)0.0120.7475 (0.7255-0.7696)NALogistic regression models showing unit OR values (per each 1-unit higher) for component parts of PAHR and PAHR (per 1 BPM higher) as predictors of in-hospital mortality. Models were adjusted for the following covariates: age, sex, race, Charlson Comorbidity Index, acute illness severity scores, rhythm (sinus rhythm vs atrial fibrillation) at transthoracic echocardiogram (sinus rhythm vs atrial fibrillation), acute coronary syndrome, heart failure, number of vasoactive drugs, invasive mechanical ventilation, dialysis, and coronary catheterization/percutaneous coronary intervention. P value for receiver operating curve comparison to PAHR represents De Long test.AUC = area under the receiver operating curve; HR = heart rate; MAP = mean arterial pressure; MPP = mean perfusion pressure; mSI = Modified Shock Index; NA = not applicable; ROC = receiver operating curve; other abbreviations as in Tables 1 and 2. Logistic Regression Models Showing Unit OR Values for Component Parts of PAHR as Predictors of In-Hospital Mortality Logistic regression models showing unit OR values (per each 1-unit higher) for component parts of PAHR and PAHR (per 1 BPM higher) as predictors of in-hospital mortality. Models were adjusted for the following covariates: age, sex, race, Charlson Comorbidity Index, acute illness severity scores, rhythm (sinus rhythm vs atrial fibrillation) at transthoracic echocardiogram (sinus rhythm vs atrial fibrillation), acute coronary syndrome, heart failure, number of vasoactive drugs, invasive mechanical ventilation, dialysis, and coronary catheterization/percutaneous coronary intervention. P value for receiver operating curve comparison to PAHR represents De Long test. AUC = area under the receiver operating curve; HR = heart rate; MAP = mean arterial pressure; MPP = mean perfusion pressure; mSI = Modified Shock Index; NA = not applicable; ROC = receiver operating curve; other abbreviations as in Tables 1 and 2. When RAP, HR, and MAP were included in the same adjusted model in lieu of PAHR, only RAP (adjusted unit OR: 1.03 per 1 mm Hg; 95% CI: 1.01-1.05; P = 0.040) and HR (adjusted unit OR: 1.013 per 1 BPM; 95% CI: 1.006-1.019; P < 0.001) remained associated with in-hospital mortality. PAHR was associated with mortality in all diagnosis groups of interest, with the strongest association in patients with acute coronary syndrome (Supplemental Table 3). PAHR performed better for discrimination of in-hospital mortality for patients with acute coronary syndrome or heart failure than for those with critical illnesses such as cardiogenic shock, cardiac arrest, sepsis, or respiratory failure. Likewise, PAHR performed better for patients with mild or no right ventricular systolic dysfunction or left ventricular systolic dysfunction, as well as for patients in sinus rhythm vs atrial fibrillation and for those who did not require critical care therapies such as positive pressure ventilation or vasoactive drugs (Supplemental Table 4). This lower performance in critically ill patients appeared to correlate with higher baseline mortality risk in patients with lower PAHR in these groups resulting in less separation and worse discrimination (Central Illustration, Figure 2, Supplemental Tables 3 and 4). After multivariable adjustment, PAHR remained incrementally associated with in-hospital mortality (adjusted OR: 1.03 per 1 BPM higher; 95% CI: 1.01-1.05; P = 0.001). Each higher quartile was associated with increased mortality (adjusted OR per quartile: 1.37; 95% CI: 1.19-1.59; P < 0.001), with substantially higher risk in the highest quartile vs the lowest (adjusted OR: 3.20; 95% CI: 1.83-5.95; P < 0.001). Patients with PAHR 10 to 20 BPM (adjusted OR: 1.66; 95% CI: 1.24-2.27; P < 0.001) or >20 BPM (adjusted OR: 1.78; 95% CI: 1.23-2.57; P = 0.002) were at a higher risk. Further adjustment for left ventricular ejection fraction did not substantively change this association (adjusted OR: 1.03 per 1 BPM higher PAHR; 95% CI: 1.01-1.04; P = 0.004). PAHR was associated with adjusted in-hospital mortality for patients with acute coronary syndrome, heart failure, and cardiac arrest, but it was not associated with in-hospital mortality for patients with cardiogenic shock, sepsis, or respiratory failure after adjustment (Supplemental Table 3). One-year mortality A total of 1,197 (22.0%) patients died within one year of CICU admission, including 765 (15.3%) of the 5,009 hospital survivors; 529 (10.6%) hospital survivors were alive at last follow-up but had follow-up duration less than one year. A stepwise increase in one-year mortality was observed with higher PAHR quartiles (Figure 4). Patients in the highest PAHR quartile had a one-year survival rate of only 56.0%; one-year survival was 52.8% for patients with PAHR >20 BPM (Central Illustration). An incremental association was observed between PAHR and one-year mortality (unadjusted HR: 1.07 per 1 BPM higher; 95% CI: 1.07-1.08; P < 0.001). Each higher PAHR quartile conferred increased mortality risk (unadjusted HR: 1.92 per each higher quartile; 95% CI: 1.81-2.03; P < 0.001), with a dramatically higher risk in the highest quartile vs the lowest (unadjusted HR: 7.31; 95% CI: 5.91-9.04; P < 0.001). Patients with PAHR 10 to 20 BPM (adjusted HR: 2.93; 95% CI: 2.58-3.32; P < 0.001) or >20 BPM (adjusted HR: 4.36; 95% CI: 3.72-5.11; P < 0.001) were at a higher risk. After multivariable adjustment, PAHR remained incrementally associated with one-year mortality (adjusted HR: 1.03 per 1 BPM higher; 95% CI: 1.02-1.04; P < 0.001). Each higher quartile was associated with greater mortality (adjusted HR per quartile: 1.35; 95% CI: 1.26-1.45; P < 0.001), with substantially higher risk in the highest quartile vs the lowest (adjusted HR: 2.70; 95% CI: 2.10-3.45; P < 0.001). Patients with PAHR 10 to 20 BPM (adjusted HR: 1.57; 95% CI: 1.37-1.81; P < 0.001) or >20 BPM (adjusted HR: 1.73; 95% CI: 1.43-2.08; P < 0.001) were at a higher risk. Further adjustment for left ventricular ejection fraction did not substantively change this association (adjusted HR: 1.03 per 1 BPM higher PAHR; 95% CI: 1.02-1.04; P < 0.001).Figure 4Kaplan-Meier Curve Depicting Association Between PAHR Quartiles and One-Year MortalityA stepwise increase in one-year mortality was observed with higher PAHR quartiles. CICU = cardiac intensive care unit; PAHR = pressure-adjusted heart rate; other abbreviations as in Figure 2. Kaplan-Meier Curve Depicting Association Between PAHR Quartiles and One-Year Mortality A stepwise increase in one-year mortality was observed with higher PAHR quartiles. CICU = cardiac intensive care unit; PAHR = pressure-adjusted heart rate; other abbreviations as in Figure 2. Discussion Summary of findings This is the first study to evaluate the prognostic implications of echocardiographic PAHR in a diverse cohort of patients admitted to the CICU. Higher PAHR was incrementally associated with higher severity of acute illness, more chronic conditions, and worse hemodynamics as assessed by TTE. Importantly, PAHR was associated with a higher risk of death during and after hospitalization, even after stratification by admission diagnosis, degree of biventricular dysfunction, rhythm at TTE, and critical care therapy utilization. PAHR showed greater discriminative ability in lower-risk patients who were less critically ill and had better biventricular function. It performed better than its component values, including the Modified Shock Index, for predicting in-hospital mortality. Finally, higher PAHR was associated with incrementally worse survival at one year, even after adjustment. PAHR for risk stratification in the CICU This is the first study to evaluate the association of TTE-derived PAHR with mortality in CICU patients. Patients with the highest PAHR had the worst biventricular function, highest filling pressures, highest pulmonary artery pressure and resistance, and lowest measures of systemic forward flow coupled with abnormal systemic vascular resistance. PAHR remained predictive of mortality after extensive adjustment for known predictors; however, the association was substantially attenuated, implying that it may serve as a simple marker of overall illness severity that can be easily calculated at the bedside, helping to quickly identify high-risk patients who need more detailed assessment. The strong predictive value in lower-risk individuals could facilitate identification of those who are at highest risk of clinical deterioration and may benefit from therapy escalation. Similarly, it may identify the lowest risk patients who may qualify for early transfer out of the CICU or those who may not require CICU admission at all. PAHR may not serve as a standalone risk metric, but its good discrimination for mortality and ease of measurement suggest that it can be integrated into future risk stratification tools within the CICU population. The prognostic value of TTE-derived hemodynamic parameters among critically ill patients with cardiovascular disease is well established.20, 21, 22,24,28, 29, 30 In several large cohort studies of CICU patients, low stroke volume; high ratio of mitral annulus early diastolic velocity to early diastolic tissue Doppler velocity (E/e’); and low values of the related composite variables, cardiac power index and left ventricular stroke work index, have demonstrated strong association with in-hospital mortality.20, 21, 22,24,29 In the current study, these adverse hemodynamic values were more common among patients with the highest PAHR, and the AUC value for mortality discrimination with PAHR compares favorably to the values reported in our prior studies for these to the aforementioned hemodynamic variables. Previous studies have shown that CICU and cardiogenic shock patients with right ventricular systolic dysfunction or biventricular dysfunction have significantly higher mortality compared to those with isolated left ventricular systolic dysfunction.30,31 PAHR dramatically stratified the presence of left ventricular, right ventricular, and biventricular systolic dysfunction. In the lowest PAHR quartile, 5/6 of patients did not have moderate or greater left ventricular systolic dysfunction or right ventricular systolic dysfunction, compared with 1/3 of patients in the highest PAHR quartile who did. PAHR has a long but sparse history as a measure of cardiovascular dysfunction and associated risk despite leveraging commonly available data in critically ill patients. The concept of PAHR was introduced nearly 30 years ago and was used to describe cardiovascular dysfunction in the context of the Multiple Organ Dysfunction Score.5 In that study, PAHR was significantly higher among surgical intensive care unit patients who died during hospitalization compared to those who survived to discharge.5 Since its introduction, fewer than 10 studies have evaluated the use of PAHR, and most of these have focused on patients with sepsis. Furthermore, all previous evaluations of PAHR have measured RAP invasively.5, 6, 7, 8, 9, 10 Only one published study (n = 1,411) has examined PAHR in patients with cardiac critical illness, finding that higher PAHR values were associated with more severe illness, increased prevalence of cardiac arrest, and more frequent use of vasoactive and inotropic therapies in patients with cardiogenic shock.10 Higher PAHR values were likewise associated with increased in-hospital mortality, regardless of the underlying precipitant of cardiogenic shock.10 Similarly, in our population, patients with the highest PAHR values were older, more critically ill, had more comorbidities, had a higher prevalence of cardiac arrest, shock, and multiorgan dysfunction, and used more critical care therapies. Importantly, PAHR stratified risk effectively among CICU patients with and without cardiogenic shock. In fact, PAHR performed better in the lower-risk group without cardiogenic shock, highlighting its potential in identifying patients early in the disease course, before progression to overt cardiogenic shock and multiorgan dysfunction, which is associated with worse prognosis.32,33 In addition, in our cohort, PAHR had better discriminative value for in-hospital mortality among patients with acute coronary syndrome compared to those with heart failure, which may also reflect better performance in patients who were less critically ill and had lower baseline risk. Our analysis validates the previously published data evaluating PAHR in cardiogenic shock.10 Furthermore, it extends on the previous work, which relied on invasively measured RAP to calculate PAHR,10 to include noninvasive estimation of RAP by TTE. Importantly, point-of-care ultrasound is frequently used in the intensive care unit setting to estimate RAP, further highlighting the widely accessible potential of PAHR to guide resuscitation efforts at the bedside in real-time.34 Long-term prognostic implications of PAHR Impressively, PAHR was associated with one-year mortality for patients admitted to the CICU who survived to hospital discharge. This emphasizes that TTE variables determined at the time of CICU admission can identify patients at risk of unfavorable post-discharge outcomes who may require closer follow-up. There are no dedicated scores to predict post-hospital outcomes in CICU survivors, although several risk scores designed to predict in-hospital mortality can be used for this purpose despite lower discrimination.33,35,36 However, these risk scores incorporate multiple clinical variables, which can be cumbersome to obtain, thus limiting utility. In contrast, PAHR is readily calculated using noninvasive hemodynamic data, which when combined with its predictive capabilities, make it an attractive alternative. PAHR vs traditional hemodynamics Although the Shock Index and Modified Shock Index, which incorporate HR and systemic blood pressure (HR/SBP and HR/MAP, respectively), can predict outcomes in patients with cardiovascular disease,37,38 these indices do not capture right ventricular hemodynamics. Among critically ill patients, right ventricular systolic dysfunction is often under-recognized and is associated with poor outcomes.39 In our cohort of CICU patients, PAHR performed better than all its component values, including the Modified Shock Index (HR/MAP) and RAP, in predicting mortality. By integrating RAP as a summary measure of right ventricular preload and diastolic function, PAHR appears to be a better marker compared to the Shock Index and Modified Shock Index and therefore can better guide triage and risk stratification. Study Limitations As with any retrospective analysis, causal relationships could not be determined, and unmeasured confounding variables may have influenced outcomes despite careful analysis. Only 43.8% of eligible patients had a consultative TTE within 24 hours and had available data to calculate PAHR. Patients without either a TTE or PAHR data on the TTE report differed systematically from those included in this analysis with more critical care diagnoses, lower prevalence of acute coronary syndrome and heart failure, and greater use of critical care therapies. As we chose not to perform imputation of missing values, excluding these patients could be a potential source of selection bias. In addition, our population was derived from a single, quaternary, academic medical center, included predominantly White males, and was historical in nature, all of which may limit generalizability. Finally, we lacked a validation cohort in this study, although our findings were consistent with the only previous evaluation of PAHR in patients with cardiac critical illness,10 thus validating previously published work. We relied on the TTE report, rather than independently reviewing original images, which inherently contributes to interindividual variability in interpretation of biventricular function and filling pressures, although this is reflective of real-world clinical practice. In addition, only a single PAHR value at the time of TTE was considered, yet we acknowledge that this is a highly dynamic measurement. We were unable to ascertain whether MAP was measured invasively or noninvasively on an individual patient level. Similarly, we were unable to determine the approach to RAP assessment (i.e, invasive measurement of central venous pressure or noninvasive estimate by TTE using inferior vena cava size and collapsibility); based on our institutional echocardiography practice, most RAP values were likely estimated noninvasively by TTE. Correct calculation of PAHR is heavily influenced by the accuracy of RAP values, which has recognized limitations for both invasive measurements and noninvasive estimation by TTE. The latter in particular has shown substantial variability in accuracy when compared with invasive measurements, particularly in critically ill patients and those treated with positive pressure ventilation.25,26,40 Despite this, PAHR was still prognostic in our cohort, similar to that observed in previous studies that used invasive RAP measurements.5, 6, 7, 8, 9, 10 This is the first study to demonstrate the prognostic value of PAHR obtained noninvasively by TTE, and this was present despite established limitations in RAP estimation, emphasizing the potential clinical utility. Finally, we did not consider the cardiac rhythm at time of TTE, except for distinguishing between atrial fibrillation and sinus rhythm, and it is well established that unstable cardiac arrhythmias and conduction system disease can contribute to hemodynamic derangements. However, even for patients with atrial fibrillation, who are susceptible to rapid ventricular response in critical illness,41 PAHR remained prognostic. Conclusions PAHR integrates hemodynamic parameters of biventricular function and filling pressures as well as vascular tone and is readily obtainable at the bedside through noninvasive methods. Among CICU patients, PAHR provides predictive value for short- and long-term mortality, regardless of admission diagnosis, biventricular function, or critical care therapies received. Given good correlation with TTE-derived hemodynamics, better performance compared to traditional parameters of HR, MAP, RAP, and Modified Shock Index, and ease of application, PAHR has the potential to guide risk-stratification, resuscitation, and escalation of critical care therapies in real-time. Further validation studies are needed to evaluate the utility of PAHR in CICU patients, with consideration of the use of point-of-care ultrasound to estimate RAP as well as evaluation of serial PAHR measurements, to ascertain its full discriminative value in this population.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: PAHR predicts in-hospital and one-year mortality among CICU patients, across a broad range of admission diagnoses, cardiac function on TTE, and critical care therapies used, performing better than its component variables and the Modified Shock Index.COMPETENCY IN PATIENT CARE: PAHR performs better for risk stratification among lower-risk patients, including those without cardiogenic shock, which can assist clinicians in identifying patients with impending clinical deterioration who may benefit from critical care therapy escalation as well as patients who may not need CICU level of care.TRANSLATIONAL OUTLOOK: PAHR has the potential to guide clinical risk stratification and resuscitation efforts of CICU patients in real time, using point-of-care ultrasound to estimate RAP. Further studies are needed for PAHR validation in the CICU patients, specifically focusing on point-of-care ultrasound for RAP estimation and serial PAHR measurements. COMPETENCY IN MEDICAL KNOWLEDGE: PAHR predicts in-hospital and one-year mortality among CICU patients, across a broad range of admission diagnoses, cardiac function on TTE, and critical care therapies used, performing better than its component variables and the Modified Shock Index. COMPETENCY IN PATIENT CARE: PAHR performs better for risk stratification among lower-risk patients, including those without cardiogenic shock, which can assist clinicians in identifying patients with impending clinical deterioration who may benefit from critical care therapy escalation as well as patients who may not need CICU level of care. TRANSLATIONAL OUTLOOK: PAHR has the potential to guide clinical risk stratification and resuscitation efforts of CICU patients in real time, using point-of-care ultrasound to estimate RAP. Further studies are needed for PAHR validation in the CICU patients, specifically focusing on point-of-care ultrasound for RAP estimation and serial PAHR measurements. Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.